Related Experiment Videos
Application of new two-sample tests to data from a randomized placebo-controlled heart-failure trial
P K Tandon1, H Stander, R P Schwarz
1Sterling Research Group, Malvern, Pennsylvania 19355.
Statistics in Medicine
|April 1, 1990
Summary
Conventional statistical tests may miss treatment benefits in congestive heart failure patients if effects vary. O'Brien tests are more sensitive, identifying patient subgroups that respond best to experimental therapies, improving exercise tolerance time (ETT).
Area of Science:
- Cardiology
- Clinical Trials
- Biostatistics
Background:
- Congestive heart failure (CHF) management requires effective therapies.
- Assessing treatment efficacy in diverse patient populations presents statistical challenges.
- Exercise tolerance time (ETT) is a key outcome measure in CHF trials.
Purpose of the Study:
- To evaluate the efficacy of four treatments in CHF patients.
- To compare the sensitivity of conventional statistical tests versus O'Brien tests for analyzing ETT data.
- To identify patient subgroups benefiting most from experimental therapies.
Main Methods:
- A randomized, placebo-controlled, double-blind trial involving 230 CHF patients.
- Analysis of ETT data using conventional two-sample tests (t-test, rank-sum test).
- Application of O'Brien's statistical tests for comparison.
Main Results:
- Conventional tests (t and rank-sum) were insensitive to therapy effects that varied within the patient population.
- O'Brien tests demonstrated greater appropriateness for the ETT data.
- O'Brien tests successfully identified subgroups with a pronounced response to the experimental therapy.
Conclusions:
- Standard statistical tests may underestimate treatment efficacy in CHF when patient responses are heterogeneous.
- O'Brien tests offer a more robust method for analyzing ETT data in CHF trials.
- Identifying responsive subgroups can optimize therapeutic strategies and improve patient outcomes in congestive heart failure.